Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial

Abstract Previous analysis of the action to control cardiovascular risk in diabetes showed an increased risk of mortality among patients receiving intensive glucose lowering therapy using conventional regression method with intention to treat approach. This method is biased when time-varying confoun...

Full description

Bibliographic Details
Main Authors: Maryam Shakiba, Maryam Nazemipour, Nasrin Mansournia, Mohammad Ali Mansournia
Format: Article
Language:English
Published: Nature Portfolio 2023-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-32855-3
_version_ 1797846038209363968
author Maryam Shakiba
Maryam Nazemipour
Nasrin Mansournia
Mohammad Ali Mansournia
author_facet Maryam Shakiba
Maryam Nazemipour
Nasrin Mansournia
Mohammad Ali Mansournia
author_sort Maryam Shakiba
collection DOAJ
description Abstract Previous analysis of the action to control cardiovascular risk in diabetes showed an increased risk of mortality among patients receiving intensive glucose lowering therapy using conventional regression method with intention to treat approach. This method is biased when time-varying confounder is affected by the previous treatment. We used 15 follow-up visits of ACCORD trial to compare the effect of time-varying intensive vs. standard treatment of glucose lowering drugs on cardiovascular and mortality outcomes in diabetic patients. The treatment effect was estimated using G-estimation and compared with accelerated failure time model using two modeling strategies. The first model adjusted for baseline confounders and the second adjusted for both baseline and time-varying confounders. While the hazard ratio of all-cause mortality for intensive compared to standard therapy in AFT model adjusted for baseline confounders was 1.17 (95% CI 1.01–1.36), the result of time-dependent AFT model  was compatible with both protective and risk effects. However, the hazard ratio estimated by G-estimation was 0.64 (95% CI 0.39–0.92). The results of this study revealed a protective effect of intensive therapy on all-cause mortality compared with standard therapy in ACCORD trial.
first_indexed 2024-04-09T17:48:35Z
format Article
id doaj.art-c3f26b35afd3469f99a0b64e76c92317
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-04-09T17:48:35Z
publishDate 2023-04-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-c3f26b35afd3469f99a0b64e76c923172023-04-16T11:10:54ZengNature PortfolioScientific Reports2045-23222023-04-011311810.1038/s41598-023-32855-3Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trialMaryam Shakiba0Maryam Nazemipour1Nasrin Mansournia2Mohammad Ali Mansournia3Cardiovascular Diseases Research Center, Guilan University of Medical SciencesDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical SciencesDepartment of Endocrinology, AJA University of Medical SciencesDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical SciencesAbstract Previous analysis of the action to control cardiovascular risk in diabetes showed an increased risk of mortality among patients receiving intensive glucose lowering therapy using conventional regression method with intention to treat approach. This method is biased when time-varying confounder is affected by the previous treatment. We used 15 follow-up visits of ACCORD trial to compare the effect of time-varying intensive vs. standard treatment of glucose lowering drugs on cardiovascular and mortality outcomes in diabetic patients. The treatment effect was estimated using G-estimation and compared with accelerated failure time model using two modeling strategies. The first model adjusted for baseline confounders and the second adjusted for both baseline and time-varying confounders. While the hazard ratio of all-cause mortality for intensive compared to standard therapy in AFT model adjusted for baseline confounders was 1.17 (95% CI 1.01–1.36), the result of time-dependent AFT model  was compatible with both protective and risk effects. However, the hazard ratio estimated by G-estimation was 0.64 (95% CI 0.39–0.92). The results of this study revealed a protective effect of intensive therapy on all-cause mortality compared with standard therapy in ACCORD trial.https://doi.org/10.1038/s41598-023-32855-3
spellingShingle Maryam Shakiba
Maryam Nazemipour
Nasrin Mansournia
Mohammad Ali Mansournia
Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial
Scientific Reports
title Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial
title_full Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial
title_fullStr Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial
title_full_unstemmed Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial
title_short Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial
title_sort protective effect of intensive glucose lowering therapy on all cause mortality adjusted for treatment switching using g estimation method the accord trial
url https://doi.org/10.1038/s41598-023-32855-3
work_keys_str_mv AT maryamshakiba protectiveeffectofintensiveglucoseloweringtherapyonallcausemortalityadjustedfortreatmentswitchingusinggestimationmethodtheaccordtrial
AT maryamnazemipour protectiveeffectofintensiveglucoseloweringtherapyonallcausemortalityadjustedfortreatmentswitchingusinggestimationmethodtheaccordtrial
AT nasrinmansournia protectiveeffectofintensiveglucoseloweringtherapyonallcausemortalityadjustedfortreatmentswitchingusinggestimationmethodtheaccordtrial
AT mohammadalimansournia protectiveeffectofintensiveglucoseloweringtherapyonallcausemortalityadjustedfortreatmentswitchingusinggestimationmethodtheaccordtrial